Pharvaris (PHVS) EBIT Growth (3y) (2023 - 2026)

Pharvaris (PHVS) EBIT Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Growth (3y) (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 38.78%
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 13.47%
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn -12.10%
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn 79.65%
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Pharvaris 2.22 Bn 1.94 Bn - 98.68%

Historic Data

Download Data
DateValue
Mar 31, 2026 98.68%
Dec 31, 2025 859,973.56%
Sep 30, 2025 99.99%
Jun 30, 2025 -30.97%
Mar 31, 2025 -1,268,207.41%
Dec 31, 2024 -42.59%
Sep 30, 2024 -38.35%
Jun 30, 2024 -27.74%
Mar 31, 2024 -29.13%
Dec 31, 2023 -2,610.84%
Sep 30, 2023 -51.60%
Jun 30, 2023 -55.56%
Mar 31, 2023 -18,381.88%